An office‐based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer

Abstract

initial responses of 43 patients treated by irradiation were followed using the assay. RESULTSThe NMP marker was identified in the urine of patients with bladder cancer at 52 kDa (NMP-52) by Western blot. The dot-ELISA detected the urinary NMP-52 marker in 92% of patients with squamous cell carcinoma, 98% with transitional cell carcinoma, and all six of those with adenocarcinoma of the bladder, with a specificity of 94%. The positive and negative predictive values (97% and 94%, respectively) and efficiency (96%) of the dot-ELISA were high. In addition, the NMP-52 tumour marker was not detected in the urine of patients who showed a response after radiotherapy. CONCLUSIONDetecting the urinary NMP-52 marker using dot-ELISA would be helpful in the rapid diagnosis and follow-up of patients with bladder cancer.

Combined use of Epithelial Membrane Antigen and Nuclear Matrix Protein 52 as Sensitive Biomarkers for Detection of Bladder Cancer

“…The most likely explanation for these results would be that EMA is expressed at a very low level on normal adenocytes, while the immune system recognizes EMA as a glycoprotein antigen on cancer cells (28, 29). NMP-52 is probably released from the nuclei of tumor cells during apoptosis (16).…”

“…It has been demonstrated that the NMP-22 concentration is higher in BC cell lines than in urothelium from normal bladder (14, 15). In this respect, Attallah et al (16) identified a urinary NMP marker at 52 kDa (NMP-52) in the urine of BC patients. Epithelial membrane antigen (EMA) is a protein that exists on the exterior cell surface of the body (17).…”

Protein Analytical Assays for Diagnosing, Monitoring, and Choosing Treatment for Cancer Patients

“…One such example is a dot ELISA, in which all samples are absorbed onto a nitrocellulose membrane. A dot ELISA on urine samples to detect nuclear matrix protein-52 in bladder cancer could be performed in 5 minutes with 97% sensitivity and 94% specificity [34]. A paper-based ELISA using chitosan and wax screen printing was developed to detect α-fetoprotein (AFP), cancer antigen-125 (CA-125), and carcinoembryonic antigen (CEA) using chemiluminescence.…”

Proteomics and genomics of urinary bladder cancer

“…Several other NMP biomarkers have been identified and evaluated for their potential as viable biomarkers via the utilization of 2-DE technology. NMP52 has been evaluated and was found to possess a sensitivity of 98% and specificity of 94% [17]. Analysis of tumor tissue has lead to the detection of six proteins, bladder cancer-associated proteins (BLCA)1-6 that were exclusively present in the tumors and adjacent "normal" bladder tissue of cancerous subjects [18].…”